摘要
目的探究曲美他嗪联合依那普利对冠心病慢性心衰患者心肌损伤标志物及心功能的影响.方法选取2021年3月—2022年4月本院收治的98例冠心病慢性心衰患者为研究对象,按随机数字表法分为两组,每组49例.对照组采用依那普利治疗,观察组采用曲美他嗪联合依那普利治疗,均持续用药2个月.对比两组患者的临床疗效、心肌损伤标志物、心功能及不良反应发生情况.结果观察组的治疗总有效为95.91%,高于对照组的81.63%,差异有统计学意义(P<0.05).治疗后,观察组的脑钠肽、心肌肌钙蛋白I、心肌肌钙蛋白T水平分别为(223.28±29.15)pg/mL、(0.31±0.04)ng/mL、(0.05±0.02)ng/mL,均低于对照组的(310.42±25.314)pg/mL、(0.92±0.14)ng/mL、(0.12±0.06)ng/mL,组间差异有统计学意义(P<0.05).治疗后,观察组的左心室舒张末期内径、左心室收缩末期内径分别为(57.06±5.72)mm、(40.62±2.84)mm,均短于对照组的(60.29±5.24)mm、(42.79±3.27)mm,左心室射血分数为(39.16±3.92)%,高于对照组的(35.14±3.74)%,6min步行距离为(326.81±69.29)m,长于对照组(290.52±54.62)m,组间差异有统计学意义(P<0.05).两组的不良反应发生率比较,差异无统计学意义(P>0.05).结论曲美他嗪联合依那普利能够显著提高冠心病慢性心衰患者的临床疗效,调节心肌损伤标志物水平,改善其心功能,且不良反应较少,值得临床推广使用.
Objective To explore the effects of trimetazidine combined with enalapril on myocardial injury markers and cardiac function in patients with chronic heart failure caused by coronary heart disease.Methods 98 patients with chronic heart failure caused by coronary heart disease admitted to the hospital from March 2021 to April 2022 were selected as the research objects,and were divided into two groups according to random number table method,with 49 cases in each group.The control group was treated with enalapril,and the observation group was treated with trimetazidine combined with enalapril,both of which lasted for 2 months.The clinical efficacy,markers of myocardial injury,cardiac function and incidence of adverse reactions were compared between the two groups.Results The total effective rate of the observation group was 95.91%,which was higher than 81.63%of the control group,and the difference was statistically significant(P<0.05).After treatment,the levels of brain natriuretic peptide,cardiac troponin I and cardiac troponin T in the observation group were(223.28±29.15)pg/mL,(0.31±0.04)ng/mL and(0.05±0.02)ng/mL,respectively,which were lower than(310.42±25.314)pg/mL,(0.92±0.14)ng/mL and(0.12±0.06)ng/mL in the control group,and the differences between the groups were statistically significant(P<0.05).After treatment,the left ventricular end-diastolic diameter and left ventricular end-systolic diameter of the observation group were(57.06±5.72)mm and(40.62±2.84)mm,respectively,which were shorter than(60.29±5.24)mm and(42.79±3.27)mm of the control group,and the left ventricular ejection fraction was(39.16±3.92)%,which was higher than(35.14±3.74)%of the control group,the 6 min walking distance was(326.81±69.29)m,which was longer than(290.52±54.62)m of the control group,and the differences between the groups were statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Trimetazidine combined with enalapril can significantly improve the clinical efficacy of patients with chronic heart failure caused by coronary heart disease,regulate the level of myocardial injury markers,improve cardiac function,and less adverse reactions,worthy of clinical promotion.
作者
赵玉红
高涛
ZHAO Yuhong;GAO Tao(Department of General Medicine,Zouping People's Hospital,Binzhou City,Shandong Province,Binzhou Shandong,256200,China;Department of Critical Medicine,Zouping People's Hospital,Binzhou City,Shandong Province,Binzhou Shandong,256200,China)
出处
《反射疗法与康复医学》
2023年第8期145-148,共4页
Reflexology And Rehabilitation Medicine
关键词
冠心病慢性心衰
曲美他嗪
依那普利
心肌损伤标志物
心功能
Chronic heart failure caused by coronary heart disease
Trimetazidine
Enalapril
Myocardial injury markers
Cardiac function
作者简介
赵玉红(1979-),女,山东滨州人,本科,主治医师,研究方向:全科医学。
